Skip to main content
. 2018 Jun 18;18:188. doi: 10.1186/s12906-018-2255-0

Fig. 8.

Fig. 8

Summary of the effects of Zyflamend on AMPK regulation by signaling pathways of LKB1 and CaMKK2. Zyflamend has been shown to inhibit castrate-resistant prostate cancer, in part, through the activation of AMPK. This activation is mediated by the increase in AMP:ATP ratio and the activation of the tumor suppressor protein LKB1 following phosphorylation by PKCζ. Simultaneously, Zyflamend inhibits the tumor promotor CaMKK2 via phosphorylation at Ser511 by DAPK